Nuvo announces co-operative drug development project with Germany's Fraunhofer Institute

    MISSISSAUGA, ON, Sept. 1 /CNW/ - Nuvo Research Inc. (TSX: NRI), a
Canadian drug development company focused on the research and development of
drug products that are delivered to and through the skin using its topical and
transdermal drug delivery technologies, and on the development of its immune
modulating drug candidate WF10, today announced a co-operative drug
development project with the Fraunhofer Institute for Cell Therapy and
Immunology IZI in Leipzig, Germany for the preclinical and clinical
development of WF10 as a potential treatment for Allergic Rhinitis.
    The Development Bank of Saxony in Germany ("SAB") announced in late
August that it will provide financial support for this co-operative project
that will be conducted in Leipzig, Germany through Nuvo Research GmbH, a Nuvo
subsidiary. Discussions are ongoing with SAB about expanding its financial
support to include preclinical and clinical development of WF10 as a potential
treatment for Rheumatoid Arthritis.
    "Teaming up with exceptional partners like the Fraunhofer Institute and
the Development Bank of Saxony should accelerate WF10's preclinical and
clinical development," said Henrich Guntermann, President and Chief Executive
Officer of Nuvo Research. "This partnership provides Nuvo with financial
support that will allow us to more effectively deploy our own resources to
develop WF10 as a needed treatment for patients who suffer from allergies and
related asthma."

    About WF10

    The immune system provides an essential defense to micro organisms,
cancer and substances it sees as foreign and potentially harmful. WF10 focuses
on supporting the immune system by targeting the macrophage, a type of white
blood cell that coordinates much of the immune system, to regulate normal
immune function. In conditions such as Allergic Rhinitis, the body's immune
system inappropriately responds to the presence of foreign allergens. Research
suggests that in some cases, WF10 may rebalance improperly functioning immune

    About Nuvo Research Inc.

    Nuvo is primarily focused on the research and development of drug
products delivered to and through the skin using its topical and transdermal
drug delivery technologies. Nuvo's lead product is Pennsaid, a topical
non-steroidal anti-inflammatory drug (NSAID). Nuvo intends to leverage its
skin-penetrating technologies to create a portfolio of topical and transdermal
products targeting a variety of indications.
    Nuvo is a publicly traded, Canadian pharmaceutical company headquartered
in Mississauga, Ontario, with manufacturing facilities in Varennes, Québec and
Wanzleben, Germany, and a research and development center in San Diego,
California. For more information, please visit

    About Fraunhofer Institute

    The Fraunhofer Institute for Cell Therapy and Immunology IZI is a member
of the Fraunhofer Group for Life Sciences. Its objective is to find solutions
for specific problems at the interfaces of medicine, life sciences and
engineering. It supports partners active in medicine-related industries and

    About Development Bank of Saxony

    SAB is the hub at the center of the many activities that traditionally
comprise regional development in Saxony, a federal state that enjoys a unique
position in both Germany and Central Europe.
    SAB is a stand-alone development bank, with no commercial banking
activities. Its business lines are recognized by the European Commission as
purely development-oriented. They support both general and highly specific
economic and social development initiatives. Working closely together with
Saxony's state government, banks and savings banks as well as the KfW banking
group, the primary objective of SAB is to develop commercial foundations and
general infrastructure, thereby securing and improving living conditions
throughout Saxony as a whole.
    SAB also advises clients on supplementary development aid available from
the German federal government, European Union and other sources, assisting
them in making their applications or developing tailor-made solutions that
bundle together resources from multiple providers. SAB acts as a single
specialized point of contact for individuals, entrepreneurs, researchers,
associations, local authorities and other institutions and organizations
operating or planning to operate in Saxony.

    This document contains forward-looking statements. Some forward-looking
statements may be identified by words like "expects", "anticipates", "plans",
"intends", "indicates" or similar expressions. These forward-looking
statements, by their nature, necessarily involve risks and uncertainties that
could cause actual results to differ materially from those contemplated by the
forward-looking statements. Nuvo considers the assumptions on which these
forward-looking statements are based to be reasonable at the time they were
prepared, but caution that these assumptions regarding future events, many of
which are beyond the control of the Company, may ultimately prove to be
incorrect. Factors and risks, which could cause actual results to differ
materially from current expectations, are discussed in the annual report, as
well as in Nuvo's Annual Information Form for the year ended December 31,
2008. Nuvo disclaims any intention or obligation to update or revise any
forward-looking statements whether a result of new information or future
events, except as required by law. For additional information on risks and
uncertainties relating to these forward looking statements, investors should
consult the Company's ongoing quarterly filings, annual report and Annual
Information Form and other filings found on SEDAR at

For further information:

For further information: For more information about Nuvo, please
contact: Adam Peeler, Media and Investor Relations, The Equicom Group Inc.,
Tel: (416) 815-0700 x225, email:

Organization Profile

Nuvo Research Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890